Cite
HARVARD Citation
Illini, O. et al. (2022). Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Therapeutic advances in medical oncology. p. . [Online].